Products | Suppliers | 登录 | 注册 | 外贸论坛
Hubei Jusheng Technology Co., Ltd.
Honesty is fundamental,Quality is life,lnnovation is power, and Service is soul!
Verified Supplier

2 Years

Home > Products > Raw Material Drug >

CAS 936563-96-1 Ibrutinib

Hubei Jusheng Technology Co., Ltd.

City: wuhan



Contact Person:MissLinda View Contact Details

CAS 936563-96-1 Ibrutinib

Brand Name : Jusheng Brand
Model Number : 936563-96-1
Certification : ISO, 9001, USP
Place of Origin : China
MOQ : 10grams
Price : Discount is possible if your order is big enough
Payment Terms : T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability : 1000kg/month
Delivery Time : within 2 working days
Packaging Details : 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
CAS : 936563-96-1
Apparence : White Powder
Purity : 99%
Email :
Skype : live: linda_8965
Whatapp : +86 18871490254
Contact Now

Oral Medical Ibrutinib PCI-32765 Anticancer Raw Material Drug CAS 936563-96-1 USAN

Quick detail

Ibrutinib, PCI-32765
CAS No.:936563-96-1
Synonyms:2-​Propen-​1-​one, 1-​[(3R)​-​3-​[4-​amino-​3-​(4-​phenoxyphenyl)​-​1H-​pyrazolo[3,​4-​d]​pyrimidin-​1-​yl]​-​1-​piperidinyl]​-;
Exact Mass:440.19600
Molecular Weight:440.49700

Ibrutinib Description

Ibrutinib (USAN, also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).
Ibrutinib was developed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma.
It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia. In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma.

Use in Cancer

Ibrutinib is approved to treat1. Chronic lymphocytic leukemia in patients who have already received other treatment.
2. Mantle cell lymphoma in patients who have already received other treatment.
3. Waldenström macroglobulinemia (a type of non-Hodgkin lymphoma).
4. Ibrutinib is also being studied in the treatment of other types of cancer.

Recommended dose modifications

Toxicity OccurrenceMCL Dose Modification After Recovery Starting Dose = 560 mgCLL and WM Dose Modification After Recovery Starting Dose = 420 mg
FirstRestart at 560 mg dailyRestart at 420 mg daily
SecondRestart at 420 mg dailyRestart at 280 mg daily
ThirdRestart at 280 mg dailyRestart at 140 mg daily
FourthDiscontinue IMBRUVICADiscontinue IMBRUVICA

Oral Administration

Administer once daily at approximately the same time each day

Swallow capsule whole, do not chew, break, open, or crush capsules

Missed dose

  • Take missed dose as soon as possible on the same day and return to normal schedule the following day
  • Do not take extra capsules to make up for the missed dose

Product Tags:

hair growth drugs


antihistaminic drugs

China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

CAS 936563-96-1 Ibrutinib Images

Send your message to this supplier
Enter your email please.
To: Hubei Jusheng Technology Co., Ltd.
Characters Remaining: (0/3000)

Français| Русский язык| Español| Português| 日本語

Home| Products| Suppliers| Site Map| About Us| Contact Us| Help| 关于我们| 联系我们

Copyright © 2009 - 2017 All rights reserved.

Inquiry Cart 0